Literature DB >> 21166704

Primary squamous cell carcinoma of the vagina: human papillomavirus detection, p16(INK4A) overexpression and clinicopathological correlations.

Victoria Fuste1, Marta del Pino, Assumpta Perez, Angel Garcia, Aureli Torne, Jaume Pahisa, Jaume Ordi.   

Abstract

AIM: To determine the role of human papillomavirus (HPV) in the pathogenesis of primary squamous cell carcinoma of the vagina (SCCVa), and to evaluate its clinicopathological significance. METHODS AND
RESULTS: All cases of SCCVa diagnosed over a 15-year period from two hospitals in Barcelona, Spain (n=32) were retrieved. Patients with a history of carcinoma of the cervix diagnosed <5 years before were excluded. HPV was detected and typed by polymerase chain reaction (PCR) using SPF10 primers. Immunohistochemistry was performed for p16 and p53. HPV was detected in 25 cases (78.1%). HPV16 was the most prevalent type. Patients with HPV-positive tumours were associated frequently with a history of carcinoma or intraepithelial neoplasia of the cervix or vulva diagnosed more than 5 years before (56% versus 0%; P=0.01). HPV-positive tumours were more frequently of non-keratinizing, basaloid or warty type than HPV-negative neoplasms (84% versus 14.3%; P<0.001), and showed diffuse positive immunoreactivity for p16(INK4a) (96%, versus 14.3%; P<0.001). The sensitivity and specificity of p16 to identify HPV-positive tumours were 96% and 85.7%, respectively.
CONCLUSIONS: A high number of SCCVs are related to HPV infection and may be identified by immunohistochemistry for p16. HPV-positive tumours tend to affect women with history of cervical neoplasia.
© 2010 Blackwell Publishing Limited.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21166704     DOI: 10.1111/j.1365-2559.2010.03727.x

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  8 in total

Review 1.  [HPV-associated alterations of the vulva and vagina. Morphology and molecular pathology].

Authors:  L-C Horn; K Klostermann; S Hautmann; A K Höhn; M W Beckmann; G Mehlhorn
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

Review 2.  [Interdisciplinary S2k guidelines on the diagnosis and treatment of vaginal carcinoma and its precursors-recommendations on surgical pathology for histopathological workup, diagnostics, and reporting].

Authors:  Lars-Christian Horn; Anne Kathrin Höhn; Monika Hampl; Grit Mehlhorn; Markus Follmann; Hans-Georg Schnürch
Journal:  Pathologe       Date:  2021-02       Impact factor: 1.011

Review 3.  HPV-related squamous cell carcinoma variants in the head and neck.

Authors:  Samir K El-Mofty
Journal:  Head Neck Pathol       Date:  2012-07-03

4.  Prevention of K-Ras- and Pten-mediated intravaginal tumors by treatment with camptothecin-loaded PLGA nanoparticles.

Authors:  Jeremy S Blum; Caroline E Weller; Carmen J Booth; Imran A Babar; Xianping Liang; Frank J Slack; W Mark Saltzman
Journal:  Drug Deliv Transl Res       Date:  2011-10-01       Impact factor: 4.617

5.  P16(INK⁴a) overexpression is associated with CDKN2A mutation and worse prognosis in HPV-negative laryngeal squamous cell carcinomas.

Authors:  Ana B Larque; Laura Conde; Sofia Hakim; Llucia Alos; Pedro Jares; Isabel Vilaseca; Antonio Cardesa; Alfons Nadal
Journal:  Virchows Arch       Date:  2015-02-05       Impact factor: 4.064

Review 6.  Progress in the pathological arena of gynecological cancers.

Authors:  W Glenn McCluggage
Journal:  Int J Gynaecol Obstet       Date:  2021-10       Impact factor: 4.447

7.  Expression of LRIG proteins as possible prognostic factors in primary vaginal carcinoma.

Authors:  Cecilia Ranhem; Gabriella Lillsunde Larsson; Håkan Hedman; David Lindquist; Mats G Karlsson; Ann-Cathrin Hellström; Ellinor Östensson; Bengt Sorbe; Kristina Hellman; Sonia Andersson
Journal:  PLoS One       Date:  2017-08-25       Impact factor: 3.240

8.  Human papillomavirus, p16(INK4A), and Ki-67 in relation to clinicopathological variables and survival in primary carcinoma of the vagina.

Authors:  K Hellman; D Lindquist; C Ranhem; E Wilander; S Andersson
Journal:  Br J Cancer       Date:  2014-02-13       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.